<DOC>
	<DOCNO>NCT03043989</DOCNO>
	<brief_summary>This clinical trial conduct recommend safe tolerable phase 2 dose docetaxel cabazitaxel combine clarithromycin men develop castrate-resistant prostate cancer . In castrate-resistant setting , resistance taxane therapy inevitably develop . Men develop resistance taxanes poor prognosis , treatment option . It believe CYP enzyme contribute docetaxel cabazitaxel resistance metastatic prostate cancer , resistance mitigate pharmacologic CYP inhibition . In study potent CYP3A inhibitor , clarithromycin , co-administered concurrently either docetaxel cabazitaxel , whose systemic metabolism dependent CYP3A4 , intent overcome resistance taxanes .</brief_summary>
	<brief_title>Cohorts Docetaxel Cabazitaxel Combination With Potent CYP3A4 Inhibitor , Clarithromycin</brief_title>
	<detailed_description>This dose-escalation study design determine maximum tolerate dose docetaxel cabazitaxel give combination clarithromycin . Eligible patient assign docetaxel cabazitaxel , base drug previously administer prior study entry . Enrollment dose level 3+3 cohort design maximum tolerate dose achieve . Docetaxel cabazitaxel administer day 1 ( 3 week ) cycle total 6 cycle . Subjects arm administer clarithromycin day -1 , 1 2 3 week cycle .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inhibitors</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>1 . Men metastatic castrateresistant prostate cancer ( prostate cancer progress despite castrate level testosterone &lt; 50 ng/dL ) , use standard measure progression define PCWG2 2 . Have receive least 4 cycle docetaxel cabazitaxel , less ten , two consecutive rise PSA value , check least 7 day apart . No PSA decline last 42 day 3 . Bone disease document either : positive bone scan , CT scan , MRI ; biopsyproven bony metastases 4 . Age ≥18 year 5 . ECOG performance status ≤ 2 ( Karnofsky ≥ 60 % ) 6 . Have normal organ marrow function define : absolute neutrophil count ≥1,500/mcL platelets ≥100,000/mcL total bilirubin ( within normal institutional limit ) AST/ALT ≤ 2.5 × ULN ( ≤ 1.5 x ULN conjunction alk phos &gt; 2.5 x ULN Docetaxel AST ≤ 1.5 x ULN Cabazitaxel creatinine clearanceno minimum Docetaxel creatinine clearance ≥ 30 mL/min/1.73 m2 Cabazitaxel 7 . No evidence clinical progression , form increase lesion crosssectional imaging , new cancerattributable symptom worsen exist symptom 8 . Ability understand willingness sign write informed consent document 1 . Patients residual toxicity &gt; Grade 2 attribute taxane therapy , except neuropathy , exclude &gt; grade 1 2 . Patients receive investigational agent within last 28 day . 3 . History allergic reaction attribute compound similar chemical biologic composition clarithromycin taxanes 4 . Patients receive medication substance inhibitor inducer CYP3A4 ineligible 5 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 6 . Received 10 cycle docetaxel [ docetaxel cohort ] 6 cabazitaxel [ cabazitaxel cohort ] 7 . Last docetaxel cabazitaxel dose &gt; 6 week prior enrollment 8 . Patients document history QT prolongation ventricular cardiac arrhythmia , include torsades de pointes , take drug know prolong QT</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>docetaxel</keyword>
	<keyword>cabazitaxel</keyword>
	<keyword>phase 1b</keyword>
	<keyword>castration-resistant</keyword>
	<keyword>bone metastasis</keyword>
</DOC>